ArticleJournal of neurogastroenterology and motility2011
The evaluation of otilonium bromide treatment in asian patients with irritable bowel syndrome.
Article in Journal of neurogastroenterology and motility, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Indian consensus statements on irritable bowel syndrome in adults: A guideline by the Indian Neurogastroenterology and Motility Association and jointly supported by the Indian Society of Gastroenterology.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2023Guideline
- Comparative Effectiveness of Mebeverine and Otilonium Bromide on Health-Related Quality of Life in Patients with Irritable Bowel Syndrome: A Prospective Cohort Study.Life (Basel, Switzerland) · 2026Article
- Expert Opinion on the Efficacy and Safety of Antispasmodics with a Focus on Irritable Bowel Syndrome.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2025Review
- 2-Amino-Molecules (Basel, Switzerland) · 2024Article
- The Efficacy of Mebeverine in the Treatment of Irritable Bowel Syndrome-A Systematic Review.Journal of clinical medicine · 2022Review
- Prevalence, clinical characteristics, and management of irritable bowel syndrome in Vietnam: A scoping review.JGH open : an open access journal of gastroenterology and hepatology · 2021Article
- Article
- Second Asian Consensus on Irritable Bowel Syndrome.Journal of neurogastroenterology and motility · 2019Review
- Efficacy of otilonium bromide in irritable bowel syndrome: a pooled analysis.Therapeutic advances in gastroenterology · 2017Article
- Bloating and functional gastro-intestinal disorders: where are we and where are we going?World journal of gastroenterology · 2014Review
- Review
- Recent advances in pharmacological treatment of irritable bowel syndrome.World journal of gastroenterology · 2014Review
- Colonic smooth muscle cells and colonic motility patterns as a target for irritable bowel syndrome therapy: mechanisms of action of otilonium bromide.Therapeutic advances in gastroenterology · 2014Review
- Role of antispasmodics in the treatment of irritable bowel syndrome.World journal of gastroenterology · 2014Review
- Irritable bowel syndrome: the evolution of multi-dimensional looking and multidisciplinary treatments.World journal of gastroenterology · 2014Review
- Long-term efficacy and safety of otilonium bromide in the management of irritable bowel syndrome: a literature review.Clinical and experimental gastroenterology · 2014Review
- Abdominal bloating: pathophysiology and treatment.Journal of neurogastroenterology and motility · 2013Review
- Pharmacological agents currently in clinical trials for disorders in neurogastroenterology.The Journal of clinical investigation · 2013Review
- Are solifenacin and ramosetron really ideal to treat irritable bowel syndrome?Journal of neurogastroenterology and motility · 2012Article
- Is otilonium bromide really effective for treating asian patients with irritable bowel syndrome?Journal of neurogastroenterology and motility · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimsAntispasmodics including otilonium bromide (OB) are recommended to treat irritable bowel syndrome (IBS). However, reports about OB experience in Asia is sparse. The purpose of present study was to provide the efficacy of OB in treating Asian IBS patients.
methodsOverall, 117 IBS patients meeting Rome II criteria were enrolled in an 8-week, double-blind, active-controlled and single center trial. Randomized participants received either OB 40 mg or mebeverine 100 mg 3 doses daily. The primary endpoints were to evaluate the net changes of abdominal pain/discomfort frequency score (APDFS) and safety profile, while the secondary endpoints were to assess the changes in abdominal pain/discomfort intensity, flatulence, abdominal bloating, satisfied stool frequency etc.
resultsFinally, 49 OB and 52 mebeverine subjects were eligible for efficacy analysis. Compared to baselines in per protocol populations, the reduced APDFSs in OB and mebeverine were 0.55 ± 1.20 (P = 0.011) and 0.37 ± 1.11 (P = 0.042), respectively, to show similarly reduced scores. The most reported side effects included dry mouth, nausea and dizziness. Besides, the improved APDFSs at 4th week visit, final alleviations in abdominal pain intensity, flatulence, abdominal bloating and satisfied stool frequency with global assessments filled by both patients and investigators were significantly achieved by both treatments, and OB was not inferior to mebeverine in treating these parameters.
conclusionsIn Orientals, OB is as effective as mebeverine for alleviating IBS symptoms in terms of abdominal pain, flatulence, abdominal bloating etc. However, obvious side effects are also observed. A large-scaled trial and post-marketing surveillance are recommended to confirm its efficacy and safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.